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The purpose of this paper is to review the effectiveness of medicinal and non-medicinal 
treatments of attention-deficit/hyperactivity disorder (ADHD).  This was accomplished through a 
comprehensive review of the literature related to this topic.  ADHD affects a large amount of the 
population with prevalence rates reported to be between 2% and 7% (Bruchmuller, Margraf, & 
Schneider, 2012).  Unfortunately, of the children who have been diagnosed with ADHD, 60% - 
85% of them continue to exhibit these symptoms in adolescence and 60% of those diagnosed 
with pediatric ADHD will see their symptoms persist into their adult lives (Madaan, Daughton, 
Lubberstedt, Mattai, Vaughan, & Kratochvil, 2008).  Moreover, contrary to popular belief, 
ADHD impairments extend far beyond the classroom to other additional facets of one’s life 
including peer interactions as well as in extracurricular activities that take place after school.  
This paper will examine the effectiveness of multiple treatment methods commonly used for this 
disorder as well as issues concerning the effects and over-prescription of stimulant medications 
has become more prominent in recent years and should be further discussed.   
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CHAPTER 1  
INTRODUCTION 
There have been several studies that have reviewed the effectiveness of both medicinal 
and non-medicinal treatments for ADHD.  Moreover, many important advances have been made 
in the treatment of ADHD including the formulation of new stimulant medications and positive 
effects of medicinal combined with behavioral treatments.  We have also gained a better 
understanding of the neurobiology of ADHD patients as well (Wigal, 2009).  Medicinal 
treatments for ADHD are plentiful in selection, but many can cause unwanted side-effects or 
sometimes discontinuation of the drug can become difficult over time.  Stimulants have been 
used to help people manage the symptoms of ADHD in children since the 1930s (Wigal, 2009).  
While stimulants are considered safe and effective forms of treatment by current standards, they 
may not be appropriate for people with comorbid diagnoses, and they also have abuse potential 
(Wigal, 2009).  The selection of non-medicinal treatments is numerous as well, but they can 
cause more effort and time.  Unfortunately, many people do not have any more time or effort to 
spare in their everyday lifestyles.  In order to obtain more immediate results, pharmaceutical 
treatments are usually used instead.   
The over-diagnosis and medicating of children and adults with ADHD has been a very 
prominent issue for quite some time now.  ADHD is said to affect 1 in 20 children in the United 
States, and 80% of these children diagnosed with ADHD will see their symptoms persist into 
adolescence (Faraone, Sergeant, Gillberg, & Biederman, 2003).  Although, it seems that even 
with as much attention this issue gets, it still does not garner as much it should.  Figure 1 (page 
4) illustrates how a rise in ADHD diagnoses has occurred in the U.S. between the years of 1998 
and 2009.  With the exception of the western region of the U.S., every part of the country has 
seen an increase in ADHD diagnoses of at least 2.1% over an eleven year span.  As a result of 
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this large number of ADHD diagnoses, some researchers believe that the heart of this issue lies 
among the imperfections within the diagnostic criteria that have been used for ADHD since 
1994.  One research study conducted in 1990 found that only 30% of children who were 
officially diagnosed with ADHD actually met the diagnostic criteria (Santich, 2008).  
Futhermore, Bruchmuller et al. discussed several studies that support improper diagnoses.  One 
study involved the re-examination of 92 children that had been referred to an ADHD clinic, they 
found that only 22% of the sample had a primary diagnosis of ADHD and only 37% had a 
secondary ADHD diagnosis (Bruchmuller, et al., 2012).  Results from these studies may suggest 
a need for a change in the present diagnostic process or criteria.  This issue should be a major 
concern among professionals.  How can we identify and implement effective treatments for 
ADHD if we are unable to properly diagnose the disorder itself? 
Figure 1. Retrieved from Center for Disease Control [CDC]/National Center for Health Statistics [NCHS], 
Health Data Interactive and National Health Interview Survey 
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Background on ADHD  
  The first documented description of ADHD-like symptoms was made by a German 
psychiatrist named Dr. Heinrich Hoffman, who published a poem entitled “Zappel Philip” (or 
“Fidgety Phillip”) in a children’s book in 1846 (Santich, 2008).  Following this, Dr. George Still 
made a series of lectures in 1902 where he discussed children who exhibit a lack of moral control 
without any physical impairment (Rowland, Lesesne, & Abramowitz, 2002).  The name of the 
disorder has also changed over the years.  Previous titles for what we now call ADHD include: 
minimal brain dysfunction, minimal brain damage syndrome, and hyperkinetic reaction of 
children (Rowland et al., 2002).  Names such as minimal brain damage syndrome and minimal 
brain dysfunction were early attempts to link the disorder to an epidemic of encephalitis that 
occurred between 1917 and 1918, subsequent research eventually proved this theory to be 
incorrect (Rowland et al., 2002).   
History of ADHD Diagnosis  
Since the first discussions and observations of ADHD were made, the symptoms for have 
described in great detail in The Diagnostic and Statistical Manual (DSM), which is widely 
known as the gold standard tool for the identification of disorders in the United States.  By the 
time the second edition of the DSM had been written the first version of ADHD was included, 
and as previously mentioned, at that time it was called “hyperkinetic reaction of children” 
(Santich, 2008, p. 91).  The term attention deficit disorder (ADD) was used in the third edition of 
the DSM in the early 1980s.  Since its inclusion into the DSM, as with many of the included 
disorders, the diagnostic criteria for ADHD has evolved and become more complex.  With each 
new addition of the DSM the criteria has had some major additions made to it.  The diagnostic 
criteria and descriptions of ADHD from the second version of the DSM (DSM – II) and the most 
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recent version of the DSM (DSM – IV – TR) are included to illustrate the significant 
evolutionary changes that have been made to its criteria since its inclusion to the manual. The 
newest edition of the DSM, the DSM – V, is scheduled to be released in May of 2013; which 
makes one wonder: what changes, omissions, or additions (if any) will be made to the diagnostic 
criteria in the new edition?   
DSM – II Diagnostic Criteria for Hyperkinetic Reaction of Childhood (or adolescence)   
This disorder is characterized by over-activity, restlessness, distractibility, and short 
attention span, especially in young children; the behavior usually diminishes in adolescence. If 
this behavior is caused by organic brain damage, it should be diagnosed under the appropriate 
non-psychotic organic brain syndrome (q.v.) (American Psychiatric Association [APA], 1968, p. 
50). 
DSM – IV – TR Diagnostic Criteria for Attention-Deficit/Hyperactivity Disorder  
A. Either (1) or (2): 
(1) Six (or more) of the following symptoms of inattention have persisted for at least 6 months to 
a degree that is maladaptive and inconsistent with developmental level: 
Inattention 
(a) Often fails to give close attention to details or makes careless mistakes in schoolwork, work, 
or other activities 
(b) Often has difficulty sustaining attention in tasks or play activities 
(c) Often does not seem to listen when spoken to directly 
(d) Often does not follow through on instructions and fails to finish schoolwork, chores, or duties 
in the workplace (not due to oppositional behavior or failure to understand instructions) 
(e) Often has difficulty organizing tasks and activities 
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(f) Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort 
(such as schoolwork or homework) 
(g) Often loses things necessary for tasks or activities (e.g., toys, school assignments, pencils, 
books, or tools) 
(h) Is often easily distracted by extraneous stimuli 
(i) Is often forgetful in daily activities 
(2) Six (or more) of the following symptoms of hyperactivity/impulsivity have persisted for at 
least 6 months to a degree that is maladaptive and inconsistent with developmental level: 
Hyperactivity 
(a) Often fidgets with hands or feet or squirms in seat 
(b) Often leaves seat in classroom or in other situations in which remaining seated is expected 
(c) Often runs about or climbs excessively in situations in which it is inappropriate (in 
adolescents or adults, may be limited to subjective feelings of restlessness) 
(d) Often has difficulty playing or engaging in leisure activities quietly 
(e) Is often "on the go" or often acts as if "driven by a motor" 
(f) Often talks excessively 
Impulsivity 
(g) Often blurts out answers before questions have been completed 
(h) Often has difficulty awaiting turn 
(i) Often interrupts or intrudes on others (e.g., butts into conversations or games) 
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present 
before age 7 years. 
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C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or 
work] and at home). 
D. There must be clear evidence of clinically significant impairment in social, academic, or 
occupational functioning. 
E. The symptoms do not occur exclusively during the course of a Pervasive Developmental 
Disorder, Schizophrenia, or other Psychotic Disorder and are not better accounted for by another 
mental disorder (e.g., Mood Disorder, Anxiety Disorder, Dissociative Disorder, or a Personality 
Disorder) (APA, 1996, p. 91-93). 
Can Improper Diagnoses Lead to Ineffective Treatment Outcomes? 
 Recently, disputes have become unavoidable concerning the controversy of whether to 
revise the DSM criteria for ADHD; much of this controversy discusses criticism of ADHD 
subtypes as well as including age specificity within the DSM – V criteria (Ghanizadeh, 2012).  
There are certain levels of subjectivity that are placed in the criteria of several different 
disorders, including ADHD, to help the clinician use his or her professional judgment or expert 
opinion regarding the degree to which the symptoms are being exhibited.  However, when 
considering ADHD, the level in which subjectivity is present in the criteria seems to be far too 
prominent.  The current system in which ADHD is diagnosed should have more concrete criteria 
to help provide a more standardized method to the diagnostic process.  As described by the APA 
DSM – V ADHD and disruptive behavior disorders work group, a criticism of the DSM-IV 
criteria is that it is “sparely described, and this enhances criterion variance, which is a major 
problem in everyday use” (Coghill & Seth, 2011, p. 79).  Another critique of the criteria is that it 
is too lengthy and difficult for clinicians to remember (Coghill & Seth, 2011).  The validity of 
the age of onset that is currently has been questioned as well.  In the DSM – IV – TR, criterion B 
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states “some hyperactive-impulsive or inattentive symptoms that caused impairment were 
present before age 7 years” (APA, 1996, p. 93).  However, DSM – IV field trials revealed that 
75% of the participants reported an age of onset of 9 to 14 years for the inattentive group of 
symptoms (Tannock, 2013).  Moreover, Tannock discussed a study that involved an adult 
population with ADHD retrospectively recalling their age of onset, the study revealed that only 
50% of the participants could recall an age of onset prior to the age of 7; 95% could confirm an 
age of onset before the age of 12; 99% could recall an age of onset before 16 years old (2013).   
Some authors have made suggestions as to what changes should be made to the 
diagnostic criteria of ADHD.  A few examples of these proposed changes include: a reduction in 
symptom threshold in adults, a replacement of subtypes with specifications of current 
presentation of symptoms, and elaboration of symptoms examples in criteria A1 and A2 (Coghill 
& Seth, 2011; Tannock, 2013).  Does treatment effectiveness depend upon proper diagnoses?  
When someone is being treated as if they have ADHD, but in all actuality they have 
Oppositional Defiance Disorder or Conduct Disorder, the effectiveness of the treatment being 
provided may provide some skewed results.   
Medicinal Treatments for ADHD 
 The treatments for ADHD are very plentiful in their selection.  Medicinal treatments are 
the most popular form of treatment used for ADHD.  Medicinal treatments are any interventions 
that utilize pharmacological properties. There are two main categories of medicinal treatments 
for ADHD: stimulants and non-stimulants.  Some examples of popular stimulant medications for 
ADHD include: Vyvanse, Adderall, and Ritalin.  Vyvanse is a type of amphetamine treatment 
called lisdexamfetamine (described on page 15), Adderall is a mixed-amphetamine salt treatment 
(described on page 16), and Ritalin is a methylphenidate (described on page 18).  Some 
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examples of non-stimulant medications include: Strattera, Intuniv, and Kapvay.  Strattera is a 
type of atomoxetine treatment (described on page 21), Intuniv is a guanfacine treatment 
(described on page 23), and Kapvay is a colonodine treatment (described on page 24).  Medicinal 
treatments have much more research citing their efficacy then non-medicinal treatments.  Even 
though medicinal treatments are widely used and numerous studies have been conducted proving 
their effectiveness, the list of possible side effects could be lengthy and potentially dangerous.       
Possible Side Effects for Medicinal Treatments 
There are several different side effects that could occur when taking any of the previously 
listed medicinal treatments.  According to the National Institute of Mental Health (NIMH), there 
are several different possible side effects that could occur, but in most instances they are minor 
and vanish with decreases in dosages (NIMH, 2012).  Some of the most common side effects for 
medicinal treatments include: a decrease in appetite, problems with sleeping, headaches, and 
stomach aches (NIMH, 2012).  Some other side effects that are less common include the 
development of tics or suddenly appearing to have an emotionless personality or flat affect 
(NIMH, 2012).  One article stated that the U.S. has a warning of possible death with misuse 
listed in the labeling for the d-amfetamine and mixed amfetamine salts combination (Elia & 
Vetter, 2010).   The authors then pointed out that “a warning to avoid use in pediatric patients 
with cardiac problems is also included for the amfetamine preparation as well as for 
methylphenidate” (Elia & Vetter, 2010, p. 169).  According to NIMH, in 2007 the Food and 
Drug Administration (FDA) required that all creators of ADHD medications provide medication 
guides for patients (NIMH, 2012).  The mandatory inclusion of these medical guides followed a 
review that found patients who have pre-existing heart conditions have a slightly higher risk for 
heart attack, strokes or even sudden death when taking ADHD medications (NIMH, 2012).  
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Non-medicinal Treatments for ADHD 
There are also several different types of non-pharmacological treatments that are widely 
used to help people with ADHD.  When treating children at a young age, treatment usually 
begins with behavioral interventions including: child, teacher, or parent training or parent 
education programs (Sonuga-Barke et al., 2013).  Parent training deals with helping parents to: 
find ways to identify and control the antecedents and consequences pertaining to the child’s 
behaviors, identifying problematic behaviors, positively reinforce appropriate social behavior, as 
well as using time-out and planned ignoring to help decrease undesired behaviors (Rajwan, 
Chacko, & Moeller, 2012; Young & Amarasinghe, 2010).  Other non-medicinal treatments for 
ADHD include: fatty acid/vitamin and mineral supplements, exclusion of artificial food 
colorings, neurofeedback, cognitive training, and restricted elimination diets (Sonuga-Barke et 
al., 2013).  Dietary interventions (i.e. supplements and elimination/exclusion diets) are described 
more fully on page 26 and 27.  Neurofeedback (described on page 25) is where someone with 
ADHD is taught to efficiently control specific brain activity patterns in order to improve 
behavioral regulation.  Cognitive training is accomplished by learning how to identify and 
control the antecedents and consequences.  Methods used for accomplishing this include: the 
child’s behaviors, identifying problematic behaviors, positively reinforcing appropriate social 
behavior, and utilizing time-out/planned ignoring to help decrease undesired behaviors 
(cognitive treatments are described on page 27 and 28).  The goal of this paper is to identify 
treatment options that have proven to effectively treat ADHD efficiently as well as provide 
suggestions as to what treatment or combination of treatments may be the safest and most 
efficient options.  This will be done by providing results and discussion regarding the efficacy or 
treatment outcomes of several different options used to treat ADHD, reviewing common 
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critiques of DSM – IV –TR diagnostic criteria, and thoughts/suggestions will be given regarding 
criteria changes in DSM – V.   
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Definition of Terms 
Adderall: Stimulant medication used to treat ADHD 
Attention-Deficit/Hyperactivity Disorder: A neurobehavioral disorder that is characterized by 
noticeable difficulties in impulsivity, hyperactivity, or inattention 
Cognitive Training: Identification and controlling of the antecedents and consequences that 
involve: the child’s behaviors, identifying problematic behaviors, positively reinforcing 
appropriate social behavior, and utilizing time-out/planned ignoring to help decrease undesired 
behaviors 
Neurofeedback: A treatment which involves learning to acquire control over specific patterns in 
brain activity in order to successfully improve self-regulation of behaviors more efficiently 
throughout daily life 
Non-pharmacological Treatment: Any form of treatment that does not involve the use of 
medicinal interventions or supplements 
Restricted Elimination Diet: The practice of eliminating certain things from one’s diet (i.e. 
sugar) in the hopes that it will result in a reduction in ADHD symptom presentation 
Ritalin: Stimulant form of medication used to treat ADHD 
Straterra: Non-stimulant form of medication used to treat ADHD 
Vyvanse: Stimulant form of medication used to treat ADHD 
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Summary of Chapter 1 
Studies have shown that there is some cause for concern regarding the effectiveness of treatment 
options for ADHD.  One study showed that 60% of the children who are diagnosed with ADHD 
will ultimately see their symptoms persist well into their adult lives (Madaan et al., 2008). 
Moreover, with the percentage of ADHD diagnoses on a constant rise in the U.S., a review of the 
available treatments and their efficacy should be conducted to help identify what options are the 
most effective.  Both medicinal and non-medicinal treatments will be considered as well as 
pairing medicinal treatment with supplemental non-medicinal interventions also.  Another issue 
in delivering treatment effectively to people with ADHD is properly diagnosis.  Providing 
effective treatments is heavily dependent upon accurate diagnoses.  One critique of the DSM 
criteria for ADHD is that it is not described with enough detail which can lead to greatly 
enhanced criterion variability (Coghill & Seth, 2011).  Studies have also been conducted that call 
into the question the validity of the age of onset currently being used in the DSM as well.  The 
following chapter will provide examples of studies that have tested and reviewed the efficacy of 
medicinal and non-medicinal treatments for ADHD.    
13 
 
CHAPTER 2 
OVERVIEW OF LITERATURE 
 Important advances in cognitive neuroscience fields, molecular/behavioral genetics, and 
neuroimaging have allowed us to obtain much more evidence that ADHD is a complicated 
neurobiological disorder that involves many different regions of the brain and a complex 
network of neurotransmitters (Antshel, Hargrave, Simonescu, Kaul, Hendricks, & Faraone, 
2011).   This makes understanding and treating the disorder a very individualized and complex 
process.  The long term effectiveness and safety of the treatments being used are both main 
concerns for people who have any kind of disorder, including ADHD.  The importance for 
people who have ADHD, and for the family of loved ones who have ADHD, to have a safe and 
effective treatment outcome is vital.  A study was conducted that reviewed the long term 
outcomes of ADHD treatments, the authors found that people who have ADHD who did not 
receive treatment often times had poorer long term outcomes  and that treatment may improve 
the lives of people with ADHD, but not necessarily to the point of healthy controls (Shaw et al., 
2012).  While on the surface this may seem like very basic information, but it is important to 
establish that any kind of treatment being provided improves the quality of life in the targeted 
areas for the individual utilizing it.   
Achieving effectiveness over a long period of time is the goal for any treatment, 
especially when considering treatments that are costly in nature.  A study was conducted that 
estimated the annual amount of money spent on ADHD treatment in the U.S. found that between 
$12,005 and $17,458 was spent per child diagnosed (Kovshoff, Williams, Vrijens, Danckaerts, 
Thompson, Yardley, Hodgkins, & Sonuga-Barke, 2011).  Keeping these numbers in mind, 
providing effective treatment is a very important goal; especially for families who are already 
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living on a fixed income.  This leaves some clinicians in a bind when providing treatment for 
individuals with ADHD.  Due to the potentially high cost for several of the treatment options for 
ADHD, clinicians are forced to take the socio-economic status of their patients into account 
when providing treatment (Kovshoff et al., 2011).  Unfortunately, the issue of treatment cost may 
also force clinicians to overlook more effective, but costly treatment options for some patients. 
Medicinal Treatments for ADHD 
For a long time now, pharmacological interventions have been at the forefront of ADHD 
treatment, and this still remains true today.  Pharmacological treatments are usually considered 
first because they treat the main symptoms of the disorder, thusly helping the person function 
more efficiently in academic, social, and home settings (Madaan et al., 2008).  Also, recent 
studies have shown that stimulants and non-stimulants have proven to be continuously effective 
beyond two year treatment periods while providing adverse effects that are both few and 
tolerable (Huang and Tsai, 2011).  Another article stated that when selecting pharmacological 
treatments, one must also take into consideration the medication’s demonstrated effect on: 
“health-related quality of life” of the individual, persistence and adherence, and cost-
effectiveness of the treatment (Hodgkins, Shaw, McCarthy, & Sallee, 2012, p. 263).   
Stimulant Medications 
 The first type of medicinal treatments that were approved by the Food and Drug 
Administration (FDA) to be prescribed to individuals with ADHD, were stimulant medications 
(Bitter, Angyalosi, & Czobor, 2012).  Pharmacological treatments are the most widely relied 
upon methods for treating ADHD, but there are several different variations of medicinal 
treatments that allow clinicians to individually tailor the duration of the treatment (i.e. active 
isomer or a mixture of active/less active isomers; medications that have immediate release, 
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intermediate release, or extended release options) to the specific needs of the patient (Antshel et 
al., 2011).  Many of the immediate release amphetamine treatments have been safely and 
effectively used to treat ADHD since the 1930’s, however, many of the studies conducted 
evaluating the safety and efficacy of these treatments were done prior to the formulation of 
diagnostic criteria (Hodgkins et al., 2012).   
 Some of the more widely used stimulant medication treatment options include: osmotic-
release oral system methylphenidate (OROS – MPH), amphetamines, mixed amphetamine salts, 
and methylphenidates.  Amphetamines have been known to induce calming, relaxing effects for 
several decades.  In the 1930’s, it was then first noted that amphetamines produced a 
paradoxically relaxing sensation among “severely disruptive, institutionalized, hyperactive boys” 
(Hodgkins et al., 2012, p.247).  This observation helped to cause many to take note of the 
benefits that stimulants may have when treating people with ADHD (Hodgkins et al., 2012).  
However, the pharmaceutical compositions that were used to treat those same symptoms are far 
different than they are today (Hodgkins et al., 2012).  As it was briefly mentioned earlier, 
stimulant medications have been pharmacologically modified so that they can immediately 
release, intermediately release, or provide an extended release of the active ingredients to help 
meet the needs of the individual with a great deal of specificity.   
 Amphetamines.  This form of medicinal treatment for ADHD has been a well-known 
option for people with ADHD for many years.  One popular ADHD amphetamine treatment is 
lisdexamfetamine, more widely known as Vyvanse.  One study that reviewed the efficacy and 
safety of lisdexamfetamine among 310 adolescents, between the ages of 13 and 17, the authors 
found that 49 of the 310 (15.8%) subjects discontinued treatment due to: “treatment-emergent 
adverse events”, “lack of efficacy”, or “treatment/baseline ECG abnormalities” (Childress & 
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Berry, 2012, p. 313).  The most commonly experienced side effects included: decreased appetite 
(33.9%), headaches (14.6%), insomnia (11.2%), and decreased weight (9.4%) (Childress & 
Berry, 2012).  A study conducted by DuPaul et al. on lisdexamfetamine found that treatment 
greatly reduced the symptoms and improved executive functioning among 24 college students, 
however, functioning was not equivalent to healthy controls (Bitter, Angyalosi, and Czobor, 
2012).  One positive aspect of lisdexamfetamine is that attempts to hasten the metabolic rate by 
administering the drug intravenously or crushing it for intranasal inhalation proved to be 
unsuccessful, this means getting a “quick high” for recreational purposes is not an option 
(Hodgkins et al., 2012).  This inability to speed up the metabolism rate for lisdexamfetamine also 
decreases the likelihood of someone overdosing from the drug (Antshel et al., 2011).  One 
interesting study using lisdexamfetamine to help increase driving efficiency, conducted by 
Biederman et al., found that the drug helped to reduce accidents, produce faster reaction times, 
and lower the rate of simulated driving collisions among 69 participants using a validated driving 
simulation paradigm (Bitter et al., 2012).   
 Another variation of amphetamines are mixed-amphetamine salts IR or XR (immediate 
release or extended release), a popular brand name of this treatment is Adderall.  A study 
conducted in 2005 found that improvements of 30% or greater on Conner’s Global Index Scale 
were maintained while using mixed-amphetamine salts IR and XR during long term treatments 
(Findling, Biederman, Wilens, Spencer, McGough, Lopez, & Tulloch).   Also, the cardiovascular 
effects for long and short- term mixed-amphetamine salt treatments were minimal when using 
doses that were less than or equal 30 mg per day on otherwise healthy participants (Findling et 
al., 2005).  Another study that reviewed the efficacy of Adderall concluded that “the efficacy of 
Adderall remained statistically significant even after adjusting for heterogeneity of study design, 
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methodology, and additional factors that could have influenced the outcomes” (Faraone & 
Biederman, 2002, p. 73).  Faraone & Biederman (2002) also found that the use of Adderall 
proved to be efficacious when treating the following symptoms: inattention, hyperactivity, and 
aggression.  Another study attempting to test the efficacy of mixed-amphetamine salts IR showed 
that, with doses of 5 mg. or higher, quick improvements in teacher ratings as well as 
mathematical performance were noticed within 1 ½ hours following treatment administration 
(Hodgkins et al., 2012).  In 2007, a study was conducted that evaluated the cardiovascular safety 
in children taking mixed-amphetamine salts XR.  The study evaluated 2,968 children between 
the ages of 6 and 12 years old, the authors found that only about 2.5% of the participants had two 
consecutive systolic blood pressure and diastolic blood pressure values greater than the 95th 
percentile (in age, sex, and height), and 3.6% had their pulse rate increase by at least 25 beats per 
minute to a value of at least 110 beats per minute (Donner, Michaels, & Ambrosini, 2007).  
Another research study that examined the long-term effects of mixed-amphetamine salts XR 
found that, based on norms provided by the Centers for Disease Control (CDC), growth deficits 
occurred in weight, height, and body mass index during year one of treatment but deficits in 
growth were not significant in the second year of treatment (Faraone, Biederman, Monuteaux, & 
Spencer, 2005).   A research study was conducted in 2001 that reviewed the effectiveness of 
Adderall treatments for adults with ADHD.  The authors found that an average oral dose of 54 
mg administered twice per day was both effective and well tolerated among the 27 participants 
(Spencer et al., 2001).  A significant reduction in the ADHD rating scale results (at least a 30% 
reduction) were found in 70% of the participants who were taking Adderall (Spencer et al., 
2001).  The authors concluded that Adderall is an effective short-term treatment for adults with 
ADHD, but more studies evaluating long-term treatment effects in adults with ADHD need to be 
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conducted (Spencer et al., 2001).  One study that evaluated the long-term effectiveness and 
tolerability of mixed-amphetamine salts resulted in treatment discontinuation, prior to the end of 
the 24 month treatment duration, in 52% of the 568 total initial enrollments (McGough et al., 
2005).  However, of the 52% who discontinued treatment only 16% did so due to adverse effects 
or because the treatment was lacking in efficacy, although, of the 568 total participants 525 of 
them (92%) reported experiencing at least one adverse effect (McGough et al., 2005).     
 Methylphenidates.  Methylphenidates (MPH) are a very widely used option for treating 
ADHD, a brand of MPH treatment is Ritalin.  Often times, MPH is one of the first forms of 
treatment that is suggested for people with ADHD, but efficacy studies have found a wide 
variety of results ranging from significant improvement to no effect at all (Castells, Ramos-
Quiroga, Rigau, Bosch, Nogueira, Vidal, & Casas, 2011).  A study examining the efficacy of 
MPH found that the efficacy of the treatment increased for every 10 mg incremental increase in 
dosage of MPH (Castells et al., 2011).  Conversely, there was a decrease in efficacy for MPH 
treatment in participants with co-morbid substance use disorders and with continuous-release 
formulations (Castells et al., 2011).  A study that was conducted evaluating the effectiveness of 
MPH treatment in adults with ADHD found that MPH alleviated symptoms of anxiety and 
appeared to show trends toward significant alleviation of depressive symptoms (Bouffard, 
Hechtman, Minde, & Iaboni-Kassab, 2003).  Bouffard et al. also found that MPH had no 
significant clinical effects on blood pressure, pulse, and weight and minimal side effects were 
reported by the participants on MPH treatment as well (2003).  A randomized, placebo 
controlled, 24 week study on MPH – ER found that treatments resulted in statistical and 
clinically significant decrease in symptoms as measured by the Wender – Reimherr adult 
attention deficit disorder scale (WRAADDS) as well as with symptoms of 
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hyperactivity/impulsivity and inattention in accordance with DSM – IV criteria (Rosler, Fischer, 
Ammer, Ose, & Retz, 2008).  At the end of treatment, 61% of the participants experienced a 30% 
reduction in their WRAADDS score, moreover, 55% reportedly felt much or very much 
improved according to results from the clinical global impression scale (Rosler et al., 2008). 
A well-known stimulant treatment option for people with ADHD is dexmethylphenidate 
(DMPH), a well-known brand name of this treatment is Focalin.  Several studies have been 
conducted reviewing the efficacy and safety of DMPH.  One of the studies that evaluates DMPH 
looked at 253 pediatric outpatient participants diagnosed with ADHD, the authors found that all 
three dosages of DMPH (10, 20, and 30 mg) were effective and safe in treatment stating that 
DMPH elicited “comparable positive therapeutic responses for all assessed doses when 
compared with placebo” (Childress, Spencer, Lopez, Gerstner, Thulasiraman, Muniz, & Post, 
2009, p. 359).  Another study that examined the safety and efficacy of DMPH – extended release 
(ER) in children with ADHD found that nearly 67.3% of the participants who were taking 
DMPH – ER rated as “very much improved” on the Clinical Global Impressions – Improvement 
(CGI – I) scale, while 32.7% had a CGI – I scale rating of “minimally improved, no change, or 
minimally worse” (Greenhill, Muniz, Ball, Levine, Pestreich, & Jiang, 2006, p. 820).  However, 
75% of the people who took DMPH – ER reported adverse events (i.e. decreased appetite 
[30.2%], headaches [24.5%], abdominal pain [13.2%], nausea [11.3%], etc.) (Greenhill et al., 
2006).  Another study that reviewed the safety and efficacy of DMPH found that a reduction in 
overall symptom ratings on the DSM – IV ADHD – Rating Scale (RS) was demonstrated; with a 
mean decrease of 13.7 (from 36.8 to 23.1, on a scale of 0 to 54) from baseline (Spencer, Adler, 
McGough, Muniz, Jiang, & Pestreich, 2007).  Based on the results from their research study, 
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Spencer et al. concluded that DMPH – ER is an effective treatment for adults with ADHD and 
the efficacy was noted by teachers, observers, patients, and clinicians consistently (2007).   
 Another popular form of methylphenidate treatments are OROS – MPH medications, a 
popular brand name for this treatment is Concerta.  One study that looked at the effectiveness of 
OROS – MPH treatment found that out of 40 participants, 4 claimed to notice substantial 
improvement, 14 noticed moderate improvement, 12 had mild improvement, and 9 having no 
improvement or felt worse (Miller – Horn et al., 2008).  Of the 40 participants who took OROS – 
MPH: only 12.5%  did not experience significant bouts with insomnia, only 2.5% had no 
significant problems with tics, 17.5% had no significant problems with a decreased appetite, and 
10% experienced no significant issues with headaches (Miller – Horn et al., 2008).  A study 
conducted by Hoare et al. (2005) assessing the 12 month efficacy and safety of OROS – MPH 
was done using the Global Assessment of Satisfaction and Adequacy scales (GAS and GAA). 
The authors found that the GAS satisfaction rate varied from 69% to 49%, also satisfaction was 
more common in higher dosage groups (54 or 36 mg), higher age groups (10 – 16 years old), and 
with those who had a diagnosis of predominantly inattentive subtype (Hoare et al., 2005).  When 
considering the safety of OROS – MPH, interestingly enough, Hoare et al. found that more 
treatment-related adverse events occurred in the two lower dosage treatment groups, occurring in 
65% of the people taking 18 mg, 64.4% of the participants taking 36 mg, and only 38.5% in the 
subjects taking 54 mg (2005).  Another study regarding the efficacy of OROS – MPH used the 
Adult ADHD Investigator System report scale (AISRS) to evaluate its effectiveness (Biederman 
et al., 2007).  The authors found that of the 67 participants to take OROS – MPH treatment, 46 
(69%) attained at least a 30% reduction in AISRS scores at the end of treatment when compared 
to baseline scores (Biederman et al., 2007).  There were no serious adverse events, although 
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some of the adverse events that occurred which eventually lead to discontinuation of the 
treatment jitteriness, irritability, depression, anxiety, elevated blood pressure, and increases in 
heart rate (Biederman et al., 2007).   
Non-stimulant Medications 
 According to research studies, between 10% and 30% of the people with ADHD seeking 
treatment either respond poorly to stimulant treatment or they experience serious adverse effects 
as a result of the treatment (Huang & Tsai, 2011).  Many of the people who fall into this category 
may find themselves taking non-stimulant medications to treat their ADHD symptoms.  There 
are several different non-stimulant treatment options for people to choose from, including: 
guanfacine, bupropion, and atomoxetine (ATX).  However, only three types of non-stimulant 
medications have been approved by the FDA, they are ATX (Strattera), guanfacine (Intuniv), and 
clonidine (Kapvay).    
 Atomoxetine.  ATX is a non-stimulant medicinal treatment for ADHD that inhibits the 
adrenaline transporter specifically (Santosh, Sattar, & Canagaratnum, 2011).  One study that 
involved ATX used the Wender – Reimherr adult attention deficit disorder scale (WRAADDS) 
(which was used to evaluate “temper, affective lability, and emotional overactivity”) to help 
them identify emotional dysregulation (Santosh et al., 2011, p. 752).  The authors found that 
patients with emotional dysregulation “exhibited a greater treatment effect to ATX for symptoms 
of ADHD than the rest of the sample” (Santosh et al., 2011, p. 755).  One of the studies 
conducted that examined the efficacy of ATX involved 384 patients receiving up to 221 weeks 
of treatment (Adler, Spencer, Williams, Moore, and Michelson, 2008).  Conners’ Adult ADHD 
Rating Scale – Investigator Rated: Screening Version (CAARS) Total ADHD Symptom scores 
were used to evaluate the efficacy of the treatment (Adler et al., 2008).  What Adler et al. found 
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was that, during treatment, the CAARS scores dropped 30.2%, and adverse events mainly 
consisted of expected pharmacological effects; these results caused them to support the long-
term safety, tolerability, and efficacy of ATX treatment for adults with ADHD (2008).  Another 
study that involved an assessment of the efficacy of ATX treatment involved a comparison of 
220 people taking ATX to 225 people taking a placebo, and symptom variations prior to and 
following treatments were assessed using the CAARS – Investigator Rated: Screening Version 
scores (Durell et al., 2013).  They found that on average, the participants taking the ATX 
treatment had their CAARS scores decrease 13%, from 39% to 26% (Durell et al., 2013).  The 
authors concluded that ATX treatment efficacy, safety, tolerability, and clinical response 
outcomes were consistent with the results of previously conducted adult studies (Durell et al., 
2013).   
Bupropion (BPN).  Another non-stimulant form of medicinal treatment for ADHD is 
BPN.  BPN is an antidepressant that is metabolized by three pharmacologically active properties 
and BPN can cause “noradrenergic, anticholinergic, and indirect dopaminergic effects” 
(Banaschewski, Roessner, Dittmann, Santosh, & Rothenberger, 2004, p. 107).  An interesting 
research study by Santosh et al (2011) found two conflicting articles that tested the efficacy of 
BPN.  One study that involved 40 participants found that BPN Sustained Release (SR) was both 
statistically and clinically superior to placebos in regard to the improvements of ADHD 
symptoms in adults, conversely, a seven week study involving 30 adults found no evidence of 
any statistical differences concerning the efficacy in the use of BPN SR, MPH, and placebos 
(Santosh et al, 2011).  One study conducted by Upadhyaya et al (2004) found that, when treating 
11 people with ADHD and nicotine dependent diagnoses with BPN, noticeable improvements 
were made in smoking behaviors but not in symptoms of ADHD (Adragna, 2012).  However, 
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another study that involved 13 participants, who were substance abusing adolescents diagnosed 
with ADHD and a mood disorder, completed a 6 month long treatment program that resulted in 
improvements in ADHD, substance use, and depression (Adragna, 2012).   Another study that 
reviewed the effectiveness of BPN made some very interesting finds.  Acheson and de Wit found 
that the use of BPN made significant improvements in measurements of lapses in attention with 
individuals who had poor baseline performances, however, BPN had no effects on the three 
standardized impulsivity measurements, including: risk taking, delay discounting, and behavioral 
inhibition (2008).  This study may lead one to conclude that BPN is effective when treating 
healthy adults, but only the symptoms involving attention.      
Guanfacine (GFN).  Much like CDN, GFN is a α2-adrenoceptor agonist. Although, 
GFN is considered to be a much more selective α2-adrenoceptor agonist than clonidine 
treatments are; where CDN binds with α2A, α2B, and α2C-adrenoceptors, GFN preferentially binds 
with postsynaptic α2A-adrenoceptors located specifically in the prefrontal cortex (Biederman et 
al, 2008).   A study that reviewed the treatment effectiveness of GFN involved 345 participants 
who were randomly assigned GFN Extended Release (ER) or a placebo (259 received GFN ER 
and 86 had the placebo) (Biederman et al, 2008).  Efficacy was measured by comparing the 
statistical treatments of the participants ADHD – RS – IV scores prior to and following 
treatments.  They found that a mean reduction in ADHD – RS – IV scores at the end of treatment 
was 16.7 compared to an 8.9 reduction in the placebo group (Biederman et al, 2008).  Another 
placebo controlled study looking at the efficacy of GFN compared four different treatment 
dosages: 1mg, 2 mg, 3 mg, and 4 mg each daily (Sallee, McGough, Wigal, Donahue, Lyne, & 
Biederman, 2009).  They found that the most dramatic reductions in ADHD – RS – IV scores 
were among the 1 mg (20.4 reduction) and 4 mg (20.9 reduction) dosages (Sallee et al, 2009).  
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Another study that involved a randomized placebo controlled study of 217 children ranging in 
age from 6 – 12 years old, 138 were randomly chosen to receive GFN ER and 79 would receive a 
placebo (Connor et al, 2010).  The treatment efficacy was measured using the CPRS.  The 
authors found that there was a mean reduction in CPRS scores of 10.9 in the GFN ER group 
compared to 6.8 in the placebo group (Connor et al, 2010).  Also, a significant reduction in the 
ADHD – RS – IV scores were recorded, with a reduction of 23.8 in the GFN ER group compared 
to only 11.5 in the placebo group (Connor et al, 2010).    
Clonidine (CDN).  Clonidine is a α2-adrenergic agonist that is approved for the treatment 
of ADHD for people between the ages of 6 and 17 (Croxtall, 2011).  There have been several 
different studies that have been conducted with the goal of measuring the efficacy of CDN.  One 
study that measured the effectiveness of CDN found that the ADHD – RS – IV scores reduced 
by 15.6 in a group taking 0.2 mg/day and 16.5 in the group taking 0.4 mg/day compared to a 
reduction of 7.5 in the placebo group (Croxtall, 2011).  A research study that looked only at ECG 
changes and the occurrence rate of adverse events caused by the use of CDN found that severe or 
moderate adverse events were seemingly common among the children randomly selected to 
utilize the treatment (Daviss et al, 2008).  Thirty-one people were selected to take CDN and 30 
were taking the placebo; of the 31 on CDN 79.4% experienced a moderate or severe adverse 
event compared to 49.2% of the placebo group (Daviss et al, 2008).  Despite these conclusions, 
the authors came to the conclusion that CDN was, overall, safe and well tolerated (Daviss et al, 
2008).  Although, they recommended that any physician prescribing the drug should be aware of 
the risk for the occurrence of bradycardia and to closely monitor the heart rate of their patients as 
well as advising them on the high likelihood that drowsiness or fatigue may occur (Davis et al, 
2008).  Also, Davis et al found that CDN caused 83.9% of the participants taking the treatment to 
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experience some kind of adverse event as a result of the drug, higher than any other treatment 
that was reviewed in the study and 25.3% higher than the participants taking MPH (2008).  
Another study that looked at the safety and efficacy of CDN ER reviewed 2 separate 8 week, 
double-blind placebo controlled multicenter trials of children aged between 6 – 17 years old 
(Ming, Mulvey, Mohanty, & Patel, 2011).  The researchers found that there was significant 
clinical improvement in the ADHD – RS – IV and CPRS – Revised scores for all participants 
who were taking 0.2 or 0.4 mg daily doses of CDN ER in comparison to those who took the 
placebo (Ming et al, 2011).  The other 8 week study found that, with the CDN ER group, ADHD 
rating scale score improvements were made starting from week 2 and reached its peak by week 5 
at the latest, and maintained that level until week 7 (Ming et al, 2011).   
Non-medicinal Treatments for ADHD 
 There are a wide number of available treatments for people who have ADHD and are 
opposed to taking any kind of prescription medications.  One non-medicinal treatment is 
neurofeedback (NF).  NF is a treatment for ADHD that involves the participants learning to 
acquire control over specific patterns in brain activity in order to successfully improve self-
regulation of behaviors more efficiently throughout their daily lives (Wangler et al, 2011).  Other 
non-medicinal treatments for ADHD require people to make changes in their diets, such as the 
exclusion of specific items or the addition of dietary supplements.  Both of these methods have 
studies that have been conducted showing improvements in common symptoms associated with 
the ADHD.  However, early studies using a highly restrictive elimination diets that have shown 
promising findings with treating children with ADHD have failed to be supported when a review 
of controlled studies were conducted (Lake, 2010).  There are also a number of interventions that 
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put an emphasis on cognitive areas through the use of cognitive behavioral treatment or cognitive 
based interventions.     
Neurofeedback 
 There have been many studies that examine the effectiveness of NF as a treatment for 
ADHD, but not many studies have been conducted that review the long-term sustainability of the 
treatment.  Although, there was at least one study that performed a 6 month follow-up on people 
with ADHD who had received NF training to help determine the sustainability of its 
effectiveness (Gevensleben et al, 2010).  They found that 38 of the participants who participated 
in the follow-up not only sustained the mean scores they attained immediately following NF 
training, but the mean score improved in every measured category over the 6 month period 
(Gevensleben et al, 2010).  The authors concluded that because of the behavioral affect that NF 
training had on the participants was successfully maintained, the clinical efficacy of this method 
is more firmly supported and NF may be more recommended as a viable treatment option over 
other behavioral treatments or medicinal treatments (Gevensleben et al, 2010).  Another study 
that looked at the effectiveness of NF used the German ADHD Rating Scale (GARS) to measure 
changes in mean scores in areas of: attention deficit, hyperactivity, impulsivity, and a total score 
(Bakhshayesh, Hansch, Wyschkon, Rezai, & Esser, 2011).  The authors found that all measured 
areas improved following NF treatment.  A mean improvement of 1.978 to 1.400 was made in 
attention deficit, 1.289 to 0.644 in hyperactivity, 1.650 to 0.978 in impulsivity, and 1.689 to 
1.072 in total score between pre and post treatment (Bakhshayesh et al, 2011).  In comparison, 
the biofeedback group in the same study made improvements in all measured areas but attention 
deficit, but the improvements were not as significant as with NF (1.147 to 0.800 in hyperactivity, 
1.594 to 1.200 in impulsivity and 1.512 to1.329 in total score) (Bakhshayesh et al, 2011).  One 
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study that compared the treatment effectiveness of NF in comparison to medication and a 
combination of NF plus medication made some interesting findings.  The authors found that 
when treating with NF alone, while not extremely significant, it was more effective than using 
medication or the combination of NF and medication (Duric, Assmus, Gundersen, & Elgen, 
2012).  One may come to the conclusion that NF is an efficacious treatment that seems to be 
producing results at a level that is comparable to the standard that has been set by stimulant 
medications.     
Dietary Interventions 
 Dietary interventions have been utilized in the treatment of ADHD for several years now.  
As previously discussed, some restrictive diets have been shown to be not as effective as it was 
once thought to be, but there are some studies that have been conducted that have shown that 
some restrictive or few foods diets can prove to be efficacious by causing a significant reduction 
in symptoms of ADHD (Pelsser, Frankena, Toorman, Savelkoul, Pereira, & Buitelaar, 2009).  In 
one study, of the 27 total children that participated in a few foods diet resulted in 70% of them 
experiencing a reduction in symptoms of ADHD, according to parental and teacher ratings, by at 
least 50% (Pelsser et al, 2009).  The authors went on to state that the extent to the diet restriction 
may affect the degree to which behavioral improvements are exhibited in that excluding too 
many foods may reduce the number of responders to the treatment and excluding a small number 
of foods (i.e. sugars or additives) may prove to be non-beneficial for children with ADHD 
(Pelsser et al, 2009).  Another study discussed some of the many vitamin and mineral 
supplements that have studies supporting their positive effects on the symptoms of ADHD 
including: zinc, magnesium, iron, and vitamin B6 (Loscalzo, 2004).  Certain minerals, like zinc, 
are known to have an indirect effect on dopamine metabolism, which is well-known to be 
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associated with ADHD (Loscalzo, 2004).  A 12 week study that was conducted involved the 
supplementation of 150 mg of zinc sulfate per day in 72 girls and 338 boys, the authors found 
that zinc was superior to the placebo in the reduction of ADHD symptoms concerning areas of: 
hyperactivity, impairments of socialization, and impulsivity (Loscalzo, 2004).  Another study 
that looked at the effects that magnesium has on ADHD symptoms found that, out of 50 children 
aged 7 to 12 who met criteria for ADHD and had documented magnesium deficiencies, after 
providing 200 mg of magnesium supplements for 6 months symptoms of hyperactivity 
significantly decreased in comparison to the control group (Loscalzo, 2004).  A study involving 
changes in ADHD symptoms as a result of iron deficiencies found that there was a 30% 
improvement in ADHD symptoms according to the Conners rating scale (Loscalzo, 2004).  
Another study that reviewed the effect that supplementing fatty acids into the diet of a person 
with ADHD might result in made some interesting conclusions.  The authors stated that out of a 
randomized controlled trial, consisting of 63 children aged 6 to 12 years old taking 
polyunsaturated fatty acids, docosahexonic, or a placebo for 4 months, fatty acid 
supplementation does not have a significant effect in improving any ADHD symptom (Ballard, 
Hall, & Kaufmann, 2010).  This conclusion was made through objective attention evaluations 
(via computers and written tests) and interpretation of Conners Rating Scale scores (Ballard et al, 
2010).          
Cognitive Treatments   
 Cognitive treatments are popular options for improvement of ADHD symptoms and can 
include: cognitive-behavioral therapy or cognitive retraining.  A study that incorporated 
cognitive-behavioral treatment (CBT) methods for adolescents that specifically worked on 
communication training, cognitive restructuring, and problems solving to help adolescents with 
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parental conflicts, the authors found that CBT showed a pre and post treatment improvement in 
several behavioral measures including a decrease in symptoms for ADHD and ODD (Toplak, 
Connors, Shuster, Knezevic, & Parks, 2008).  Another study examined the efficacy of meta-
cognitive treatments on adults with ADHD.  The meta-cognitive approach uses cognitive-
behavioral techniques help develop skills in: time management, planning, and organization 
(Solanto et al, 2010).  This study compared meta-cognitive therapy with supportive therapy; they 
found that the higher the CAARS – S subscale baseline scores for inattention and memory were 
resulted in a more prominent differential improvement with the use of meta-cognitive therapy 
(Solanto et al, 2010).  Another study examining the efficacy of cognitive retraining found that it 
had positive effects on selective attention, divided attention, and sustaining of attention 
(Rajender, Malhotra, Bhatia, Singh, & Kanwal, 2012).  In this study, participants were given 36 
manualized cognitive retraining sessions that incorporated activities that focused the three 
previously mentioned areas of attention, the authors found that a change in The Attention 
Deficit/Hyperactivity Disorder Test (ADHDT; a norm based test for the diagnosis of ADHD) 
mean score total between pre and post treatment was from 128.0 to 108.3, respectively (Rajender 
et al, 2012).  This led the authors to conclude that at least 36 hours of manualized cognitive 
retraining can partially improve cognitive deficits in children with ADHD (Rajender et al, 2012).       
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Summary of Chapter 2 
 Several studies are available that evaluate, discuss, and measure the efficacy and safety of 
stimulant and non-stimulant  medicinal treatments for ADHD, but not quite as much for the non-
pharmacological treatments.  The efficacy for medicinal treatments are well supported, however, 
the amount of adverse events that occur with each prescription treatment can vary in frequency 
and intensity.  Non-medicinal treatments like NF and cognitive interventions seem to be just as 
effective, and in some cases with NF, slightly superior to medicinal treatments.  Although, more 
research is needed that evaluates the efficacy of NF and CBT for treating people with ADHD.  
Dietary interventions were also shown to exhibit improvements in symptoms of ADHD in 
participants.  However, the results from the dietary interventions seem to be quite variable in 
their findings and conclusions at times.   
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CHAPTER 3 
DISCUSSION AND IMPLICATIONS 
 In a society where it is customary to have what you want at the exact moment that you 
need it causes treatment effectiveness to be largely based upon the time it takes to notice the 
expected changes.  Unfortunately, this mindset may lead many to seek out pharmaceutical 
interventions wen treating ADHD.  The main problem with this fact is that many of the people 
who are affected by ADHD are children under the age of 12, not to mention that many medicinal 
treatments produce a myriad side effects that could occur to varying degrees of severity and 
frequency.  However, some of the side effects are seemingly covert to parents or teachers around 
the children so they can be easily overlooked or diminished by the immediate and positive 
improvements of the treatment.  Based on the research on non-medicinal treatment options 
compiled for this paper, NF appeared to be the most efficacious and produced the most 
significant improvements on symptoms of ADHD.  Medicinal treatment comparison studies will 
be discussed to help evaluate and determine conclusions as to which pharmacological 
intervention exhibits superior effectiveness.   
Treatment Comparison Studies 
 Many studies have been conducted that have compared the overall efficacy of stimulant 
versus non-stimulant medications.  In a study that compared the effectiveness of OROS – MPH 
with ATX found that CGI – I scores at the end of treatment was 83.3% to 63.6%, respectively, 
indicating that a more significant response in the OROS – MPH group (Yildiz, Sismanlar, 
Memik, Karakaya, & Agaoglu, 2011).  Yildiz et al then go on to state that while both types of 
medications are effective in the treatment of ADHD, the results show that much more prominent 
positive effects were reported by teachers and parents (2012).  In another study, a comparison 
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was made between the effectiveness of MPH with buspirone (BSP) found that, out of 34 
children, there were no significant statistical differences in the effectiveness of the treatments, 
but MPH did prove to be more effective than BSP with improving symptoms of inattention 
(Davari-Ashtiani, Shahrbabaki, Razjouyan, Amini, & Mazhabdar, 2010).  While there were no 
serious adverse side effects, more occurrences of side effects were reported from the MPH group 
(most commonly reported side effects were decreased appetite [11] and sleep [7]) than in the 
BSP group (most commonly reported side effects were tics [4] and dizziness [3]) (Davari-
Ashtiani et al, 2010).  Based on the available treatment comparison studies OROS – MPH seems 
to have the best efficacy and safety among medicinal treatments.   
Medicinal and Non-medicinal Treatment Combination Studies 
 Some studies have been conducted that involve the use of medicinal treatments along 
with psychosocial interventions and treatments.  One study randomly assigned 103 children 
between the ages of 7 – 9 with ADHD, who have responded to short-term MPH treatment, one of 
the following three treatments for 2 years: only MPH, MPH with psychosocial treatment (i.e. 
psychotherapy, training in organizational skills, and academic remediation), or MPH with 
attention control (Hechtman et al, 2004).  The functioning levels of the participants were 
assessed through academic tests, parental ratings, and self-ratings (for self-esteem and 
depression) (Hechtman et al, 2004).  The authors found that there was no significant differences 
in the treatment effectiveness for MPH in comparison with MPH plus psychosocial treatment or 
MPH with attention control, although, there were prominent improvements among all treatment 
options that were successfully sustained over a 2 year period (Hechtman et al, 2004).  Another 
study that was conducted by NIMH randomly assigned 579 children with ADHD one of four 
following treatments: intensive behavioral interventions, medication management, a combination 
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of the previous two interventions, and community treatment (the control group) (Brown et al, 
2005).  They found that, over time, there were improvements in all four treatment groups with 
the combined treatment and medication management showing the greatest improvements (Brown 
et al, 2005).  Interestingly enough, only the treatment group that had the combination treatment 
proved to maintain consistently greater improvements over the community treatment method 
across areas like parent/child relations, social skills, or disruptive behaviors (Brown et al, 2005).    
Research Limitations 
 The efficacy of medicinal treatments has been extensively reviewed over the years.  This 
is largely because medicinal treatments are very widely used, and they have been used to treat 
ADHD for several decades now.  While there are some studies that have directly compared the 
effectiveness of multiple different treatments, there is limited research on comparisons of 
different medicinal treatments as well as medicinal treatments compared to non-medicinal 
treatments.  The need for more updated research in these areas would help to bolster the evidence 
of treatments that are superior over others.  Also, this may help to inform anyone who is affected 
by the disorder what treatment methods may best for them or their loved ones.  Another issue 
with the existing research is that there is a lack of efficacy studies on non-medicinal treatments.  
There are several well supported non-medicinal treatments (i.e. NF and CBT), but many dietary 
interventions (i.e. supplements) go unnoticed that could prove to be effective for those who are 
do not want to deal with the side effects of medications.  Conducting studies that compare non-
medicinal treatments would also help to pinpoint non-pharmacological treatments that prove to 
be superior to others.  It would also be interesting to see a study that combined non-medicinal 
treatments for ADHD (i.e. NF plus dietary interventions) to test if this could be a possible option 
for some, or perhaps researchers could find that doing so increases the efficacy of the selected 
34 
 
non-medicinal treatments.  In summation, more research is needed that compares medicinal and 
non-medicinal treatments.  Moreover, comparison studies for different medicinal drugs and 
comparison studies of non-medicinal methods may prove to be beneficial as well.   
Future Implications for Treatment 
 Treatment for people with ADHD, as with treatment for any neurological disorder, will 
certainly evolve and progress over time.  With the improvements of computers that monitor brain 
activity and with the creations of better medications that treat the symptoms more efficiently, 
ADHD could and most likely will be treated in a completely different way 25 years from now.  
Moreover, the newest edition of the DSM is scheduled to be released in May of 2013.  There 
have been many professionals clamoring for a change to the way in which we currently diagnose 
people with ADHD, and until the new DSM is released we will be using the criteria that are 
already in place.  An article that discussed rumored changes to the way in which ADHD is 
diagnosed cited three major changes which included: the expansion of criterion A to include a 
higher number of symptoms for hyperactivity/impulsivity and more in-depth descriptions, 
changing the maximum age of onset in criterion B to 12 years old, and reformulation of the 
subtypes as well (Sibley, Waxmonsky, Robb, & Pelham, 2013).  According to the authors, these 
proposals are currently under review (Sibley et al, 2013).  One interesting point made by the 
authors was that recent studies involving genetics and imaging results have not found any clear 
evidence supporting the existence of ADHD subtypes as separate and distinct entities (Sibley et 
al, 2013).  Keeping all of this in mind, the diagnosis, and therefore the way in which we treat 
people with ADHD has a high likelihood that it will change in some aspect or another.   
 When considering the treatments that professionals have at their disposal for treating 
people with ADHD, it is very likely that most people will choose medications over non-
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medicinal treatments.  Due to the immediacy in which medicinal treatments work, more people 
are likely to choose to medicate versus waiting several days before noticing results.  Many 
people will be forced to weigh out the benefits of the medications with the adverse effects that 
the medications cause for the person taking it in order to decide if the immediate effects are 
worth the risk of experiencing serious side effects.  As previously mentioned, NF was a very 
effective form of non-medicinal treatment for ADHD, even when compared to some proven 
effective medications.  While the effect of NF takes time it does not, however, cause any side 
effects.     
 Unfortunately, in the opinion of this writer, we will not see an end to medicinal treatment 
for ADHD any time soon.  Acquiring prescription medications is far easier, and produces results 
in a much more timely fashion than treatments like NF or CBT.  Because of this more people 
will turn to medications, despite the occurrence of adverse side effects that they may cause.  
While it is extremely rare, there have been some documented sudden deaths of people who were 
taking stimulant medications.  According to the World Health Organization, between the years of 
1999 and 2003 there were 25 people who were taking stimulant medications who suddenly died 
(8 of them [7 pediatric; 1 adult] on MPH and 17 [12 pediatric; 5 adults] on amphetamine) 
(Wilens, Prince, Spencer, & Biederman, 2006).  Even though this is considered to be a very rare 
risk, there still is a chance that it could happen.  No matter how minimal the risk, for some, it is 
going to be too high when it involves someone they love.  Parents, teachers, and clinicians 
should be certain to take into consideration the patient’s personal pre-existing health conditions 
before deciding upon a specific type of treatment.  For example, if someone has a pre-existing 
heart condition, it would be a good idea if he/she did not take any medications where any 
cardiovascular effects are a possibility.  We should be moving in a direction where medicinal 
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treatments used solely as a short-term solution as opposed to an ongoing problem, but in order to 
do that we need to conduct more studies that prove the efficacy of non-medicinal treatments.   
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